EXPM:ZSANQ - Post Discussion
Post by
Humanist on Oct 25, 2019 9:36am
ZSAN LAUNCHES PHASE 2/3 STUDY FOR CLUSTER HEADACHE
Zosano launches Phase 2/3 study of zolmitriptan for cluster headache Oct. 24, 2019 10:33 AM ET|About:
Zosano Pharma Corporation (ZSAN)|By:
Douglas W. House, SA News Editor
Enrollment is underway in a 120-subject Phase 2/3 clinical trial evaluating Zosano Pharma's (ZSAN +3.5%) C213 (zolmitriptan) for the acute treatment of cluster headache.
C213 is a patch worn on the skin based on the company's ADAM technology, drug-coated titanium micro-projections that deliver the drug through the skin. It is the same approach used with migraine patch Qtrypta.
The co-primary endpoints are the proportion of patients achieving pain relief within 15 minutes and the proportion of patients achieving sustained pain relief (15 minutes to 60 minutes).
The estimated completion date is April 2021.
Be the first to comment on this post